Target intelligence / Profile preview

Vibrio cholerae O1 Ogawa and Inaba lipopolysaccharide antigen (null)

Target
null
Molecular classification
Bacterial surface antigen, Lipopolysaccharide (LPS), Glycoconjugate, Cell wall component (Gram-negative), Other
01

Overview

The **Vibrio cholerae O1 Ogawa and Inaba lipopolysaccharide (LPS) antigen** is a major surface polysaccharide of *Vibrio cholerae* O1, the dominant cause of cholera epidemics[1][5][9]. Its structure consists of lipid A, a core oligosaccharide, and a repeating O-specific polysaccharide (O-SP). The Ogawa and Inaba serotypes differ by a single chemical modification: the Ogawa serotype's terminal perosamine unit is 2-O-methylated, while the Inaba terminal perosamine has a hydroxyl group at that position[1][3][5][9]. This small difference results in distinct antigenic properties, which dictate serotype-specific immune recognition and are targets for vibriocidal antibodies after infection or vaccination[5][9]. Anti-LPS antibodies are strong correlates of cholera protection, making these antigens central to subunit vaccine and monoclonal antibody development[5][1]. Because LPS is also an endotoxin, there are potential concerns about reactogenicity if large doses are administered, but in the context of natural infection and vaccination, these antigens are essential mediators of both disease and protective immunity[1][5].

Other names
Vibrio cholerae O1 LPS OgawaVibrio cholerae O1 LPS InabaV. cholerae O1 LPSV. cholerae O1 O-specific polysaccharide (O-SP)Ogawa LPSInaba LPSCholera LPS antigen
02

Mechanism of action

Induction of protective antibody responses (by immune system or vaccine); Antibody-mediated neutralization

03

Biological functions

Immune response inductionAntigenicity (serotype determination)Structural component of outer membraneProtection from host defenseOther
04

Disease associations

Infection (Cholera)Antigenic determinant for cholera immunityVaccine target
05

Safety considerations

Endotoxin activity (potential for sepsis if freely circulating)Immune hyperstimulation
06

Interacting drugs

cholera vaccines

1 more in the full profile.

07

Biomarkers

Serum anti-LPS antibody titers (vibriocidal antibody response)

Beyond the preview

Go deeper on Vibrio cholerae O1 Ogawa and Inaba lipopolysaccharide antigen (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibrio cholerae O1 Ogawa and Inaba lipopolysaccharide antigen (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call